These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 22248695

  • 1. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C.
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A, WEF Study Group.
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [Abstract] [Full Text] [Related]

  • 7. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
    Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, Renner EL, Lilly LB.
    Ann Hepatol; 2014 Oct; 13(5):525-32. PubMed ID: 25152985
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [Abstract] [Full Text] [Related]

  • 10. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C, Jesudian A, Zeuzem S, Jacobson I.
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [Abstract] [Full Text] [Related]

  • 11. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA, Kanwal F.
    Clin Infect Dis; 2012 Jan 01; 54(1):96-104. PubMed ID: 22156853
    [Abstract] [Full Text] [Related]

  • 12. New developments in HCV therapy.
    Kronenberger B, Zeuzem S.
    J Viral Hepat; 2012 Jan 01; 19 Suppl 1():48-51. PubMed ID: 22233414
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F.
    J Infect; 2014 Jan 01; 68(1):1-20. PubMed ID: 24012819
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.